SPOTLIGHT: Analyst lengthens timeline for Cervarix


A Morgan Stanley analyst is raising the prospect that GlaxoSmithKline's Cervarix could be delayed five years beyond the 2009 approval expected by most analysts on Wall Street. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.